Gentil M A, Castro de la Nuez P, Gonzalez-Corvillo C, de Gracia M C, Cabello M, Mazuecos M A, Rodriguez-Benot A, Ballesteros L, Osuna A, Alonso M
Nephrology, Hospital Virgen Del Rocio, Sevilla, Spain.
Trasplante, Coordinacion Autonomica De Trasplante, Andalucia, Spain.
Transplant Proc. 2016 Nov;48(9):2867-2870. doi: 10.1016/j.transproceed.2016.07.036.
Non-heart-beating donors (NHBD) are an increasing source of organs for kidney transplantation (KT) compared with donation after brain death (DBD), but the results in each regional transplantation program require local analysis. We compared 164 KT from NHBD (83 Maastrich type II A-B [T2] and 81 type III [T3]) with 328 DBD controls. NHBD kidneys were implanted with less cold ischemia, mean time on renal replacement therapy for NHBD recipients before transplantation was less too, and a higher proportion of thymoglobulin was also used. Besides NHBD-T2 more frequently showing the A group and patients being younger (48.9 ± 11 vs DBD 55.2 ± 15 years old; P < .001), there was a lower proportion of retransplant recipients and HLA sensitization; HLA-DR compatibility was slightly worse. Proportion of nonfunctioning allograft and necessity of dialysis after transplantation for NHBD were 4.9 and 68.3% versus DBD 4.3 and 26.9% (P < .001); renal function after a year was significantly less in NHBD (serum creatinine 1.79 ± 0.9 mg/dL vs 1.46 ± 0.5 in DBD; P < .001). NHBD recipient survival rates were 96% and 96% for the 1st and 3rd years, respectively, versus 96% and 94% for DBD, respectively (not significant [NS]). Graft survival rates censored by death were 91% and 89% (1st and 3rd years, respectively) versus 95% and 94% for DBD, respectively (NS). We did not find significant differences about survival between NHBD-T2 and T3. In the multivariable survival study (Cox, covariables with statistical significance demonstrated previously in our region), NHBD is not a prognosis factor for recipient or graft survival. Regarding current criteria for choosing donors and the graft allocation applied in Andalusia, short-term survival for NHBD transplantation is similar to DBD. Renal function in the short term is slightly worse, which is why it is important to monitor results over a long term, especially those from NHBD-T2.
与脑死亡后捐赠(DBD)相比,非心脏跳动供体(NHBD)作为肾移植(KT)的器官来源正日益增加,但每个区域移植项目的结果都需要进行本地分析。我们将164例来自NHBD的肾移植(83例马斯特里赫特II A - B型[T2]和81例III型[T3])与328例DBD对照进行了比较。NHBD肾移植时冷缺血时间更短,NHBD受者移植前接受肾脏替代治疗的平均时间也更短,并且使用抗胸腺细胞球蛋白的比例也更高。除了NHBD - T2组更频繁地表现为A组且患者更年轻(48.9±11岁,而DBD组为55.2±15岁;P <.001)外,再次移植受者和HLA致敏的比例更低;HLA - DR配型略差。NHBD移植后移植肾无功能的比例和透析的必要性分别为4.9%和68.3%,而DBD组分别为4.3%和26.9%(P <.001);一年后的肾功能在NHBD组明显较差(血清肌酐1.79±0.9mg/dL,而DBD组为1.46±0.5mg/dL;P <.001)。NHBD受者第1年和第3年的生存率分别为96%和96%,而DBD组分别为96%和94%(无显著差异[NS])。因死亡而截尾的移植物生存率第1年和第3年分别为91%和89%,而DBD组分别为95%和94%(NS)。我们未发现NHBD - T2和T3在生存率方面存在显著差异。在多变量生存研究(Cox模型,协变量为我们地区先前已证明具有统计学意义的变量)中,NHBD不是受者或移植物生存的预后因素。就安达卢西亚目前选择供体的标准和应用的移植物分配而言,NHBD移植的短期生存率与DBD相似。短期内肾功能略差,这就是长期监测结果很重要的原因,尤其是来自NHBD - T2的结果。